Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy

Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy

Introduction: It is believed that the reason of the leukemic clone cell resistance to treatment with tyrosine kinase inhibitors during chronic myeloid leukemia (CML) is mutations in the genome of an early bone marrow progenitor cells that are CD34-positive. Such cells, regardless of treatment, acqui...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2015
Автори: Sviezhentseva, I.O., Perekhrestenko, T.P., Bilko, D.I., Gordienko, A.I., Diachenko, M.V., Dyagil, I.S.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2015
Назва видання:Experimental Oncology
Теми:
Original contributions
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/145458
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy / I.O. Sviezhentseva, T.P. Perekhrestenko, D.I. Bilko, A.I. Gordienko, M.V. Diachenko, I.S. Dyagil // Experimental Oncology. — 2015. — Т. 37, № 1. — С. 70-72. — Бібліогр.: 17 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-145458
record_format dspace
spelling irk-123456789-1454582019-01-23T01:23:10Z Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy Sviezhentseva, I.O. Perekhrestenko, T.P. Bilko, D.I. Gordienko, A.I. Diachenko, M.V. Dyagil, I.S. Original contributions Introduction: It is believed that the reason of the leukemic clone cell resistance to treatment with tyrosine kinase inhibitors during chronic myeloid leukemia (CML) is mutations in the genome of an early bone marrow progenitor cells that are CD34-positive. Such cells, regardless of treatment, acquire ability to proliferation and differentiation. This leads to the re-expansion of the CD34⁺ cells. Aim: to determine the CD34 antigen expression in bone marrow and peripheral blood cells in CML patients with different response to imatinib therapy using the results of hematopoietic cells culturing and the data of flow cytometry. Methods: Bone marrow aspirate from 39 patients who were treated with imatinib was studied with cytogenetic, flow cytometry and culture methods in vitro. Results: In patients with an optimal response to imatinib therapy the number of colonies was 1.8 times lower than the number of those in the group of patients with a suboptimal response to therapy. In turn, in patients with failure of imatinib therapy the number of colonies was the highest and was 2.1 times higher than the patients with optimal response. The results of cytometric studies have shown that the number of CD34⁺ cells in bone marrow was significantly higher compared to the number of CD34⁺ cells in peripheral blood cells and increased with the acquisition of leukemic cells the resistance to imatinib. There was a direct correlation between the number of colonies and clusters in semisolid agar in vitro and the number of CD34⁺ cells in the bone marrow of patients. Conclusions: The correlation between the number of CD34⁺ cells and the number of cell aggregates in semisolid agar in vitro indicates the prognostic value of the method for determining CD34⁺ cells in the patient bone marrow. The parallel increase of their number in the peripheral blood will allow developing express methods for the detection of individual patient response to imatinib therapy. Key Words: chronic myeloid leukemia, imatinib, cell culture in vitro, CD34⁺ cells. 2015 Article Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy / I.O. Sviezhentseva, T.P. Perekhrestenko, D.I. Bilko, A.I. Gordienko, M.V. Diachenko, I.S. Dyagil // Experimental Oncology. — 2015. — Т. 37, № 1. — С. 70-72. — Бібліогр.: 17 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/145458 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Sviezhentseva, I.O.
Perekhrestenko, T.P.
Bilko, D.I.
Gordienko, A.I.
Diachenko, M.V.
Dyagil, I.S.
Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy
Experimental Oncology
description Introduction: It is believed that the reason of the leukemic clone cell resistance to treatment with tyrosine kinase inhibitors during chronic myeloid leukemia (CML) is mutations in the genome of an early bone marrow progenitor cells that are CD34-positive. Such cells, regardless of treatment, acquire ability to proliferation and differentiation. This leads to the re-expansion of the CD34⁺ cells. Aim: to determine the CD34 antigen expression in bone marrow and peripheral blood cells in CML patients with different response to imatinib therapy using the results of hematopoietic cells culturing and the data of flow cytometry. Methods: Bone marrow aspirate from 39 patients who were treated with imatinib was studied with cytogenetic, flow cytometry and culture methods in vitro. Results: In patients with an optimal response to imatinib therapy the number of colonies was 1.8 times lower than the number of those in the group of patients with a suboptimal response to therapy. In turn, in patients with failure of imatinib therapy the number of colonies was the highest and was 2.1 times higher than the patients with optimal response. The results of cytometric studies have shown that the number of CD34⁺ cells in bone marrow was significantly higher compared to the number of CD34⁺ cells in peripheral blood cells and increased with the acquisition of leukemic cells the resistance to imatinib. There was a direct correlation between the number of colonies and clusters in semisolid agar in vitro and the number of CD34⁺ cells in the bone marrow of patients. Conclusions: The correlation between the number of CD34⁺ cells and the number of cell aggregates in semisolid agar in vitro indicates the prognostic value of the method for determining CD34⁺ cells in the patient bone marrow. The parallel increase of their number in the peripheral blood will allow developing express methods for the detection of individual patient response to imatinib therapy. Key Words: chronic myeloid leukemia, imatinib, cell culture in vitro, CD34⁺ cells.
format Article
author Sviezhentseva, I.O.
Perekhrestenko, T.P.
Bilko, D.I.
Gordienko, A.I.
Diachenko, M.V.
Dyagil, I.S.
author_facet Sviezhentseva, I.O.
Perekhrestenko, T.P.
Bilko, D.I.
Gordienko, A.I.
Diachenko, M.V.
Dyagil, I.S.
author_sort Sviezhentseva, I.O.
title Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy
title_short Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy
title_full Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy
title_fullStr Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy
title_full_unstemmed Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy
title_sort functional activity of cd34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2015
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/145458
citation_txt Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy / I.O. Sviezhentseva, T.P. Perekhrestenko, D.I. Bilko, A.I. Gordienko, M.V. Diachenko, I.S. Dyagil // Experimental Oncology. — 2015. — Т. 37, № 1. — С. 70-72. — Бібліогр.: 17 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT sviezhentsevaio functionalactivityofcd34positivecellsinchronicmyeloidleukemiapatientswithdifferentresponsetoimatinibtherapy
AT perekhrestenkotp functionalactivityofcd34positivecellsinchronicmyeloidleukemiapatientswithdifferentresponsetoimatinibtherapy
AT bilkodi functionalactivityofcd34positivecellsinchronicmyeloidleukemiapatientswithdifferentresponsetoimatinibtherapy
AT gordienkoai functionalactivityofcd34positivecellsinchronicmyeloidleukemiapatientswithdifferentresponsetoimatinibtherapy
AT diachenkomv functionalactivityofcd34positivecellsinchronicmyeloidleukemiapatientswithdifferentresponsetoimatinibtherapy
AT dyagilis functionalactivityofcd34positivecellsinchronicmyeloidleukemiapatientswithdifferentresponsetoimatinibtherapy
first_indexed 2023-05-20T17:22:12Z
last_indexed 2023-05-20T17:22:12Z
_version_ 1796153140024705024

Схожі ресурси